Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed trials have results

Key Signals

3 recruiting1 with results

Enrollment Performance

Analytics

Phase 2
4(80.0%)
N/A
1(20.0%)
5Total
Phase 2(4)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07118202Not ApplicableRecruiting

TheraBionic P1 Device in Subjects With Advanced Hepatocellular Carcinoma

Role: collaborator

NCT04327700Phase 2Terminated

Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib

Role: collaborator

NCT07130903Phase 2Recruiting

Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer

Role: collaborator

NCT05776524Phase 2Recruiting

Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer

Role: lead

NCT04797884Phase 2Unknown

Electromagnetic Fields Versus Placebo For Child-Pugh A and B Patients With Advanced Hepatocellular Carcinoma

Role: lead

All 5 trials loaded